POINT Biopharma Global Inc. Common Stock
PNT was delisted on the 26th of December, 2023.
109 hedge funds and large institutions have $446M invested in POINT Biopharma Global Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 48 increasing their positions, 27 reducing their positions, and 17 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
78% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 27
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
3% more funds holding
Funds holding: 106 → 109 (+3)
5% less capital invested
Capital invested by funds: $470M → $446M (-$24.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$26.6M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$13.6M |
| 3 |
State Street
Boston,
Massachusetts
|
+$9.48M |
| 4 |
OCAM
Onex Canada Asset Management
Toronto,
Ontario, Canada
|
+$5.66M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$21.9M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$10.2M |
| 3 |
DM
Deerfield Management
New York
|
-$7.73M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$7.56M |
| 5 |
BlackRock
New York
|
-$5.63M |
PNT Hedge Fund Activity: Q4 2022 in Review
109 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q4 2022, worth a combined $446M — down 5.3% from $470M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PNT positions and 17 closed out — a net gain of 3 holders — while 48 added to existing stakes and 27 trimmed.
The largest buyer was BVF Inc, adding an estimated $26.6M. The largest seller was Fairmount Funds Management, exiting entirely with an estimated $21.9M sold.
- 109 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q4 2022, up from 106 in Q3 2022.
- Funds reported $446M of POINT Biopharma Global Inc. Common Stock stock for Q4 2022, down 5.3% quarter-over-quarter.
- 20 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q4 2022 and 17 closed out, a net change of +3 holders.
- The largest POINT Biopharma Global Inc. Common Stock buyer in Q4 2022 was BVF Inc, an estimated $26.6M added.
- The largest POINT Biopharma Global Inc. Common Stock seller in Q4 2022 was Fairmount Funds Management, an estimated $21.9M sold.
Based on aggregated 13F filings for Q4 2022.